Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 16/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297295 | 0.87 | CTSS (0.52) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL8536013 | 0.86 | CTSS (0.56) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL6448979 | 0.86 | CTSS (0.56) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL9848334 | 0.86 | CTSS (0.56) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7329863 | 0.85 | REN (0.54) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7284721 | 0.85 | CTSS (0.55) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7265165 | 0.84 | CTSS (0.50) | CTSSCTSKRENCTSDCTSE | |
| SCHEMBL7311911 | 0.84 | REN (0.57) | CTSSCTSKREN | |
| SCHEMBL7272241 | 0.83 | REN (0.58) | CTSSCTSKREN | |
| SCHEMBL7266599 | 0.83 | REN (0.58) | CTSSCTSKREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220272-A1 | Propargyl glycine amino propargyl diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-11-04 | — | — | US | disclosed |
| US-6777572-B2 | PROPARGYL GLYCINE AMINO PROPARGYL DIOL DERIVATIVES ARE USEFUL AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION. | PHARMACIA CORPORATION (OF PFIZER INC.) | 2004-08-17 | — | — | US | disclosed |
| US-6667414-B2 | Renin inhibitors; hypertensive agents | PHARMACIA CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030144542-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of renal failure | HANSON GUNNAR J (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030135066-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of congestive heart failure | HANSON GUNNAR J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030130522-A1 | Use of propargyl glycine amino propargyl diol compounds for prevention of hypertension | HANSON GUNNAR J (US) | 2003-07-10 | — | — | US | disclosed |
| US-6342624-B1 | INHIBITION OF ENZYMES WITH PEPTIDES | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | disclosed |
| US-6281235-B1 | CONTROL OF HYPERTENSION. | G.D. SEARLE & CO. | 2001-08-28 | — | — | US | disclosed |
| US-5508295-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5461074-A | Dipropargyl containing aryl/alkyl sulfur/or sulfonyl/or sulfoxide terminated aminodiol compounds are used as renin inhibitor; therpeutical | G.D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5330996-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5268391-A | Cardiovascular disorders | C. D. SEARLE & CO. (US) | 1993-12-07 | — | — | US | disclosed |
| US-5246969-A | Oligopeptides as renin inhibitors | G. D. SEARLE & CO. (US) | 1993-09-21 | — | — | US | disclosed |
| WO-1993009108-A1 | AMINO ACYL AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009086-A1 | PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144542-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of renal failure | REN, AGTR1, GRHPR | CTSS 4680/4885CTSK 4052/4885REN 1/4885 |
| US-20040220272-A1 | Propargyl glycine amino propargyl diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | CTSS 4568/4885CTSK 3991/4885REN 1/4885 |
| US-20030135066-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of congestive heart failure | REN, AGTR1, AGTR2 | CTSS 4633/4885CTSK 4152/4885REN 1/4885 |
| US-20030130522-A1 | Use of propargyl glycine amino propargyl diol compounds for prevention of hypertension | REN, AGTR1, GRHPR | CTSS 4408/4885CTSK 3877/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.